{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    10,
    14,
    16,
    17,
    18,
    19,
    20,
    24,
    25,
    39,
    40,
    41,
    42
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Rationale for Amendment 3",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2.4.3",
        "sectionTitle": "Rationale for Changes in Amendment 3",
        "description": "Reference from Document History to section explaining rationale for Amendment 3."
      },
      {
        "id": "ref_2",
        "name": "Tumor Assessment Clarification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.4/7.2.1",
        "sectionTitle": "Schedule of Activities/Tumor Assessments",
        "description": "Reference from Document History clarifying that tumor assessments will be conducted as per local practice after approval of Amendment 3."
      },
      {
        "id": "ref_3",
        "name": "Tumor Assessment Flowchart Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Tumor Assessment Requirements Flow Chart",
        "description": "Reference from Document History clarifying changes to tumor assessment procedures post-Amendment 3, as detailed in the flowchart."
      },
      {
        "id": "ref_4",
        "name": "Prohibited Medications Clarification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.5.1",
        "sectionTitle": "Prohibited Medications",
        "description": "Reference from Document History clarifying permitted medications for patients who discontinued palbociclib/placebo."
      },
      {
        "id": "ref_5",
        "name": "Human PK Data Update",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2.1.2",
        "sectionTitle": "Human Pharmacokinetic Data",
        "description": "Reference from Document History for Amendment 2 indicating an update to the PK data section."
      },
      {
        "id": "ref_6",
        "name": "Table 3 Dose Modification Update",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3.4.2.3",
        "sectionTitle": "Table 3",
        "description": "Reference from Document History for Amendment 2 noting added language to Table 3 regarding criteria for treatment restart."
      },
      {
        "id": "ref_7",
        "name": "Ocular Safety Assessments",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.2.2",
        "sectionTitle": "Ocular Safety Assessments",
        "description": "Reference from Document History for Amendment 1 regarding the addition of ocular safety assessment procedures."
      },
      {
        "id": "ref_8",
        "name": "Appendix 4 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "RECIST version 1.1 Guidelines",
        "description": "Reference from Document History for Amendment 1 noting alignment of terminology with RECIST version 1.1 guidelines in Appendix 4."
      },
      {
        "id": "ref_9",
        "name": "Appendix 8 Addition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Wisconsin Age-Related Eye Disease Study (AREDS) 2008 Clinical Lens Opacity Grading Procedure",
        "description": "Reference from Document History for Amendment 1 noting the addition of Appendix 8."
      },
      {
        "id": "ref_10",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "SCHEDULE OF ACTIVITIES",
        "description": "In-text reference to the SCHEDULE OF ACTIVITIES for details on routine safety relevant assessments."
      },
      {
        "id": "ref_11",
        "name": "List of Tables",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "LIST OF TABLES",
        "description": "Reference to the list of tables in the protocol, including Table 1, Table 2, Table 3, and Table 4."
      },
      {
        "id": "ref_12",
        "name": "List of Appendices",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "APPENDICES",
        "description": "Reference to the list of appendices, including Appendices 1, 2, 3, 4, and 8."
      },
      {
        "id": "ref_13",
        "name": "Fulvestrant Data Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2.1.8",
        "sectionTitle": "Interim Analysis Data from Phase 3 Study A5481023",
        "description": "In-text reference to Section 1.2.1.8 regarding Fulvestrant."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Active Treatment Phase: Assessments should be performed prior to dosing on the visit day unless otherwise indicated. Acceptable time windows for performing each assessment are described in the column headers. No time window is to be considered for treatment schedule of palbociclib/placebo. One cycle consists of 28 days. A cycle could be longer than 28 days if persistent toxicity delays initiation of the subsequent cycle. Day 1 of any cycle visit should coincide with the day the palbociclib/placebo treatment begins. If there are delays due to toxicity, then the start of the next cycle visit will be delayed until the patient has recovered and can begin study treatment again. Fulvestrant injection will be given every 28 days (+/- 7 days) with the exception of Cycle 1 during which it will be administered on Days 1 and 15 (±2 days allowed according to the protocol visit time windows). Goserelin will be administered every 28 days (+/- number of days allowed according to the protocol visit time windows). The active treatment phase is ongoing as long as the patient is receiving both study drugs (ie, palbociclib/placebo and fulvestrant) or fulvestrant alone.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_2",
        "text": "Cycle 1/Day 1: Blood chemistry, hematology, and physical examination not required if acceptable screening assessment is performed within 7 days prior to randomization.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_3",
        "text": "End of Treatment/Withdrawal: Visit to be performed as soon as possible but no later than 4 weeks from the last dose of investigational products and prior to initiation of any new anticancer therapy. Obtain assessments if not completed during the previous 4 weeks on study.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_4",
        "text": "Post Treatment Follow-up: Patients who discontinue study treatment should be contacted 28 calendar days (±7 days) after discontinuation of study treatment (palbociclib/placebo or fulvestrant) to assess if there have been any new adverse events and/or any change to any previously reported adverse events. This follow-up should occur 28 calendar days (±7 days) regardless of any new anti-cancer therapy that may have started. Telephone contact is acceptable. Follow-up visits to assess survival status will be conducted every 3 months going forward after approval of Amendment 3. See table footnote s (Survival Follow-up) below.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_5",
        "text": "Informed Consent: Informed consent must be obtained prior to any protocol required assessments being performed (with the exception of certain imaging assessments if meeting the criteria defined in the Screening Section).",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_6",
        "text": "Ophthalmology Examinations: Upon approval of Amendment 1, newly enrolled lens grading evaluable patients will undergo an ophthalmic examination by an ophthalmologist at screening, during study treatment on Cycle 4 Day 1, on Cycle 7 Day 1, on Cycle 13 Day 1 (ie, after 3, 6 and 12 months), every 12 months thereafter (ie, Days 1 of Cycles 25, 37, etc.) and at the End of Treatment/Withdrawal visit. Additional ophthalmic examinations may be performed as clinically indicated. It is expected that a minimum of 100 evaluable patients will participate in these examinations. Sites will be informed once these examinations are no longer required for patients newly enrolled in this study. Refer to the Ocular Safety Assessments Section for further details. Upon approval of Amendment 3, ophthalmology tests will continue to be collected.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_7",
        "text": "Laboratory tests: Hematology includes hemoglobin, WBC, absolute neutrophil count, platelet count. Hematology tests must meet retreatment criteria prior to administering palbociclib Blood chemistry includes AST/ALT, alkaline phosphatase, sodium, potassium, magnesium, total calcium, total bilirubin, blood urea nitrogen (BUN) (or urea), serum creatinine, and albumin. Additional hematology/chemistries panels may be performed as clinically indicated. Upon approval of Amendment 3, hemoglobin A1c will be measured in all patients every 3 cycles (Day 1) going forward (C7D1, C10D1, C13D1, etc) and at the End of Treatment/Withdrawal visit. Pregnancy test (serum) at screening only for women of childbearing potential. Test may be repeated as per request of IRB/IECs or if required by local regulations. Serum estradiol and Follicle stimulating hormone (FSH) levels are analysed at screening to confirm postmenopausal status of women <60 years old and who have been amenorrheic for at least 12 consecutive months. Upon approval of Amendment 3, blood chemistry will be performed every 3 cycles (Day 1) going forward (C7D1, C10D1, C13D1, etc) and at the End of Treatment/Withdrawal visit. Hemoglobin A1c will be tested at the time of blood chemistry. If an adverse event occurs that mandates blood chemistry to be performed (eg, hepatic function abnormality), the additional laboratory data will be recorded in the CRF.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_8",
        "text": "CT/MRI Scans of Chest, Abdomen, Pelvis: Upon approval of Amendment 3, tumor assessments will be performed as per local practice. Refer to the tumor assessment requirement flowchart.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_9",
        "text": "Survival Follow-Up: Upon approval of Amendment 3, for patients who discontinue study treatment, survival data will be collected every 3 months going forward. Telephone contact is acceptable. During follow-up visits the following data will be recorded in the CRF: 1) start, stop and type of new anticancer therapy; 2) tumor response of new anticancer therapy; 3) date of progression of the disease during or after the new antitumor agent; 4) survival status.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_10",
        "text": "Screening scans must occur within 4 weeks (ie, 28 days) prior to randomization unless otherwise specified.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Tumor Assessment Requirements Flowchart",
        "pageNumber": 20
      },
      {
        "id": "annot_11",
        "text": "During treatment period, upon approval of Amendment 3: tumor assessment must be done according to local practice: if tumor assessments are scheduled as per the original protocol, upon approval of Amendment 3 they can be performed at a different schedule if this is common practice at that institution or it is recommended by the physician according to the patient’s clinical conditions. Selection of imaging studies will depend on treating physician and radiologist as per local practice. Upon approval of Amendment 3, RECIST 1.1 may be used to evaluate imaging assessments but will not be mandatory. Evaluation of imaging studies will be conducted as per the practice at the institution.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Tumor Assessment Requirements Flowchart",
        "pageNumber": 20
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-10-20",
        "description": "Final Protocol Amendment 3, incorporating changes to reduce safety and efficacy assessments after meeting primary endpoint.",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_2",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2014-09-30",
        "description": "Protocol Amendment 2, incorporating prospective monitoring of hemoglobin A1c and updates to pharmacokinetic data.",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_3",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2014-04-04",
        "description": "Protocol Amendment 1, incorporating ocular safety assessments and changes to study drug administration instructions.",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_4",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2013-07-24",
        "description": "Original protocol document."
      }
    ],
    "summary": {
      "referenceCount": 13,
      "annotationCount": 11,
      "versionCount": 4
    }
  }
}